As_2O_3对HPV感染阳性的宫颈癌治疗及降低宫颈癌癌前病变风险的研究
|
摘要
宫颈癌是常见妇科恶性肿瘤之一，发病率和死亡率在女性恶性肿瘤中居第二位。每年用于宫颈癌筛查和治疗的医疗费用非常巨大。宫颈癌病变的演进与高危型人乳头瘤状病毒HPV的持续感染有非常紧密的联系。HPV持续感染宫颈后，通过其基因产物干扰正常的细胞周期调节，导致细胞的连续增殖与恶性转化。因此，阻断HPV对宫颈的感染及感染后的恶性转化是预防宫颈癌发生的根本途径。由于从癌前病变-宫颈上皮内瘤样变(cervical intraepithelial neoplasia，CIN)发展到宫颈癌大约需要十年的时间，所以充分利用好病变发展演进的这段时间，在病变进入高速发展的不可逆期以前进行有效干预，可使宫颈癌成为可预防和可治愈的疾病。一种满意的治疗宫颈癌的药物，除了能纠正肿瘤细胞中的缺陷基因的表达，还应该能够清除HPV病毒。
As_2O_3是传统中药砒霜的有效成分，近年来它被证明是一种广谱的抗癌药物，对治疗急性早幼粒白血病有显著疗效。本论文探讨了As_2O_3对宫颈癌的治疗、预防作用，并研究了其作用的可能机制。通过As_2O_3对培养的人宫颈癌细胞及动物模型的实验结果进行分析，我们首次提出，As_2O_3是通过线粒体途径和激活JNK／p38／GADD45以及p53信号通路诱导宫颈癌细胞凋亡；并且通过影响细胞的胞外基质粘附、迁移能力抑制宫颈癌细胞侵袭转移。我们用促有丝分裂剂——佛波脂(TPA)化学诱导的人宫颈上皮细胞转化模型，在体内、外研究了As_2O_3对宫颈细胞恶性转化的影响，发现As_2O_3显著抑制TPA诱导的HPV阳性的宫颈上皮永生化细胞的恶性转化，表明As_2O_3具有良好的宫颈癌化学预防及治疗作用，为其更好的应用于抗肿瘤临床应用提供了基础。
Carcinoma of the cervix is one of the most common malignancies in women,second most common malignancy in both incidence and mortality. There is a bigfinancial and laborious burden for cervical cancer screening and treatment everyyear. Highly pathogenic human papillomavirus (HPV) is closely associated withprogression of cervical cancer. Continous infection of HPV interfering with cellulargrowth regulatory proteins contributes to malignant transformation of cells. Ittakes almost ten years for cervical epithelium to develop from HPV infection tocervical intraepithelial neoplasia and ultimate cervical cancer. Cervical cancer canbe treated and prevented if we can take full use of the period during theprogression of cervical cancer. A satisfying therapeutic reagent for cervicalcancers should elinimate the continuous effects of HPV, as well as correcting thedefect gene expression in cancer cells.
As_2O_3 has been indicated as a broad-spectrum anticancer medicine andsuccessfully employed in the treatment of acute promyelocytic leukemia (APL).Here we aim to show the promising future of As_2O_3 as a satisfying therapeuticreagent in cervical cancer treatment and the understanding of the mechanisms ofAs_2O_3 action. Study of cell features and tumor mouse model by As_2O_3demonstrates that As_2O_3 has a therapeutic effect on cervical cancer in vitro and invivo. In the present study, we show that As_2O_3 can induce cervical cancer cellsapoptosis through the mitochondrial pathway by downregulating expression ofHPV E6/E7 and activating JNK/p38/GADD45 and p53 signal pathways; As_2O_3 can also inhibit attachment of tumor cells to Fibronectin and Matrigel, reduce cellmotility and inhibit tumor invasion potential. In our exeriment, we also designedto evaluate the potential of As_2O_3 to inhibit the induction of malignanttransformation of TPA-immortalized and HPV-positive cervical epithelial cells invitro and in vivo (TPA is a potent tumor-promoting compound.). In our study, As_2O_3appears to decrease the risk of developing pre-invasive and invasivemalignancies in cervical epithelial cells. Our studies enlarged the range of As_2O_3usage in cervical cancer treatment and prevention, suggesting a potential clinicalapplication in cervical cancer therapies.
As_2O_3是传统中药砒霜的有效成分，近年来它被证明是一种广谱的抗癌药物，对治疗急性早幼粒白血病有显著疗效。本论文探讨了As_2O_3对宫颈癌的治疗、预防作用，并研究了其作用的可能机制。通过As_2O_3对培养的人宫颈癌细胞及动物模型的实验结果进行分析，我们首次提出，As_2O_3是通过线粒体途径和激活JNK／p38／GADD45以及p53信号通路诱导宫颈癌细胞凋亡；并且通过影响细胞的胞外基质粘附、迁移能力抑制宫颈癌细胞侵袭转移。我们用促有丝分裂剂——佛波脂(TPA)化学诱导的人宫颈上皮细胞转化模型，在体内、外研究了As_2O_3对宫颈细胞恶性转化的影响，发现As_2O_3显著抑制TPA诱导的HPV阳性的宫颈上皮永生化细胞的恶性转化，表明As_2O_3具有良好的宫颈癌化学预防及治疗作用，为其更好的应用于抗肿瘤临床应用提供了基础。
Carcinoma of the cervix is one of the most common malignancies in women,second most common malignancy in both incidence and mortality. There is a bigfinancial and laborious burden for cervical cancer screening and treatment everyyear. Highly pathogenic human papillomavirus (HPV) is closely associated withprogression of cervical cancer. Continous infection of HPV interfering with cellulargrowth regulatory proteins contributes to malignant transformation of cells. Ittakes almost ten years for cervical epithelium to develop from HPV infection tocervical intraepithelial neoplasia and ultimate cervical cancer. Cervical cancer canbe treated and prevented if we can take full use of the period during theprogression of cervical cancer. A satisfying therapeutic reagent for cervicalcancers should elinimate the continuous effects of HPV, as well as correcting thedefect gene expression in cancer cells.
As_2O_3 has been indicated as a broad-spectrum anticancer medicine andsuccessfully employed in the treatment of acute promyelocytic leukemia (APL).Here we aim to show the promising future of As_2O_3 as a satisfying therapeuticreagent in cervical cancer treatment and the understanding of the mechanisms ofAs_2O_3 action. Study of cell features and tumor mouse model by As_2O_3demonstrates that As_2O_3 has a therapeutic effect on cervical cancer in vitro and invivo. In the present study, we show that As_2O_3 can induce cervical cancer cellsapoptosis through the mitochondrial pathway by downregulating expression ofHPV E6/E7 and activating JNK/p38/GADD45 and p53 signal pathways; As_2O_3 can also inhibit attachment of tumor cells to Fibronectin and Matrigel, reduce cellmotility and inhibit tumor invasion potential. In our exeriment, we also designedto evaluate the potential of As_2O_3 to inhibit the induction of malignanttransformation of TPA-immortalized and HPV-positive cervical epithelial cells invitro and in vivo (TPA is a potent tumor-promoting compound.). In our study, As_2O_3appears to decrease the risk of developing pre-invasive and invasivemalignancies in cervical epithelial cells. Our studies enlarged the range of As_2O_3usage in cervical cancer treatment and prevention, suggesting a potential clinicalapplication in cervical cancer therapies.
引文
1. Aronson SM. Arsenic and old myths. R I Med 1994;77(7):233-4.
2. Y L Kwong, D Todd. Delicious poison:Arsenic trioxide for the treatment of leukemia. Blood 1997;89(9):3487.
3. Waxman S, Anderson KC. History of the development of arsenic derivatives in cancer therapy. Oncologist 2001 ;6 Suppl 2:3-10.
4. Gallagher RE. Arsenic--new life for an old potion. N Engl J Med 1998;339 (19): 1389-91.
5. Novick SC, Warrell RP Jr. Arsenicals in hematologic cancers. Semin Oncol 2000;27(5): 495-501.
6. Snow ET. Metal carcinogenesis: mechanistic implications. Pharmacol Ther 1992;53(1): 31-65.
7. Zhao CQ, Young MR, Diwan BA, Coogan TP, Waalkes MP. Association of arsenic-induced malignant transformation with DNA hypomethylation and aberrant gene expression. Proc Natl Acad Sci U S A 1997;94(20): 10907-12.
8. Goering PL, Aposhian HV, Mass MJ, Cebrian M, Beck BD, Waalkes MP. The enigma of arsenic carcinogenesis: role of metabolism. Toxicol Sci 1999;49 (1):5-14.
9. Hei TK, Liu SX, Waldren C. Mutagenicity of arsenic in mammalian cells: role of reactive oxygen species. Proc Natl Acad Sci U S A 1998;95(14):8103-7.
10. Chen H, Liu J, Merrick BA, Waalkes MP. Genetic events associated with arsenic-induced malignant transformation: applications of cDNA microarray technology. Mol Carcinog 2001 ;30 (2):79-87.
11. Wang TS, Shu YF, Liu YC, Jan KY, Huang H. Glutathione peroxidase and catalase modulate the genotoxicity of arsenite. Toxicology 1997; 121(3): 229-37.
12. Zhang P, Wang S, Hu L, Qiu F, Yang H, Xiao Y, et al. [Seven years' summary report on the treatment of acute promyelocytic leukemia with arsenic trioxide—an analysis of 242 cases]. Zhonghua Xue Ye Xue Za Zhi 2000;21(2):67-70.
13．孙鸿德，马玲，胡晓晨，等．癌灵Ⅰ号结合中西医辩证治疗急性早幼粒白血病32例．中国中西医结合杂志1992：12(3)：170-171．
14．张鹏，王树叶，胡龙虎，等．三氧化二砷注射液治疗72例急性早幼粒细胞白血病．中华血液学杂志1996；17(2)：58-61．
15. Chen GQ, Zhu J, Shi XG, et al. In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia: As2O3 induce NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RARalpha/PML proteins.Blood 1996,88:1052
16. Mervis J. Ancient remedy performs new tricks. Science 1996;273(5275):578.
17. Soignet SL, Maslak P, Wang ZG, Jhanwar S, Calleja E, Dardashti LJ, et al. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med 1998;339(19):1341-8.
18．张春，胡晓晨，赵晓刚．亚砷酸注射液治疗慢性粒细胞白血病．中国中医药信息杂志2003；10(3)：51．
19. Vey N. Arsenic trioxide for the treatment of myelodysplastic syndromes. Expert Opin Pharmacother 2004;5(3):613-21.
20. Bahlis NJ, McCafferty-Grad J, Jordan-McMurry I, Neil J, Reis I, Kharfan-Dabaja M, et al. Feasibility and correlates of arsenic trioxide combined with ascorbic acid-mediated depletion of intracellular glutathione for the treatment of relapsed/refractory multiple myeloma. Clin Cancer Res 2002;8(12):3658-68.
21．孟秀琴，艾工文．18例多发性骨髓瘤临床分析．临床血液学杂志2005；18(1)：40-41．
22．钱军，秦叔逵，何泽明．三氧化二砷注射液治疗中晚期原发性肝胆癌的临床研究．中华肿瘤杂志2001；23(6)：487．
23．项颖，黄风鸣．三氧化二砷注射液治疗中晚期原发性肝癌16例报告．临床肿瘤学杂志2003；8(1)：36—37．
24．朱安龙，刘连新，朴大勋，等．应用二氧化二砷连续区域化疗治疗肝癌．中华肝胆外科杂志2003；9(4)：205—206．
25．宋建功，贾利敏，孔东亮．经胃镜局部注射砷剂治疗中晚期食管癌临床研究．中国医学理论与实践2002；4：434．
26．竺涵光，王跃平，张志远，等．三氧化二砷经导管动脉介入治疗口腔鳞癌(附3例报告)．口腔医学纵横杂志2000；16(1)：35—36．
27．秦叔逵，钱军，何泽民，等．三氧化二砷注射液治疗晚期胆囊癌．临床肿瘤学杂志2000；5(4)：286—287．
28．郑作深，饶健．亚砷酸注射液治疗盲肠癌术后复发获完全缓解一例．临床肿瘤学杂志2001；6(4)：37．
29. Vuky J, Yu R, Schwartz L, Motzer RJ. Phase Ⅱ trial of arsenic trioxide in patients with metastatic renal cell carcinoma. Invest New Drugs 2002;20(3):327-30.
30. Dalton WS. Targeting the mitochondria: an exciting new approach to myeloma therapy. Commentary re: N. J. Bahlis et al, Feasibility and correlates of arsenic trioxide combined with ascorbic acid-mediated depletion of intracellular glutathione for the treatment of relapsed/refractory multiple myeloma. Clin. Cancer Res, 8: 3658-3668, 2002. Clin Cancer Res 2002;8(12):3643-5.
31. Ohnishi K, Yoshida H, Shigeno K, Nakamura S, Fujisawa S, Naito K, et al. Arsenic trioxide therapy for relapsed or refractory Japanese patients with acute promyelocytic leukemia: need for careful electrocardiogram monitoring. Leukemia 2002; 16(4):617-22.
32. Soignet SL, Frankel SR, Douer D, Tallman MS, Kantarjian H, Calleja E, et al. United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol 2001 ;19(18):3852-60.
33. Ohnishi K, Yoshida H, Shigeno K, Nakamura S, Fujisawa S, Naito K, et al. Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia. Ann Intern Med 2000;133(11):881-5.
34. Barbey JT, Soignet S. Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia. Ann Intern Med 2001;135(9):842-3.
35. Huang SY, Chang CS, Tang JL, Tien HF, Kuo TL, Huang SF, et al. Acute and chronic arsenic poisoning associated with treatment of acute promyelocytic leukaemia. Br J Haematol 1998; 103(4): 1092-5.
36. Camacho LH, Soignet SL, Chanel S, Ho R, Heller G, Scheinberg DA, et al. Leukocytosis and the retinoic acid syndrome in patients with acute promyelocytic leukemia treated with arsenic trioxide. J Clin Oncol 2000;18(13):2620-5.
37. Roberts TF, Sprague K, Schenkein D, Miller KB, Relias V. Hyperleukocytosis during induction therapy with arsenic trioxide for relapsed acute promyelocytic leukemia associated with central nervous system infarction. Blood 2000;96(12):4000-1.
38. Mathews V, Balasubramanian P, Shaji RV, George B, Chandy M, Srivastava A. Central nervous system relapse in a patient with acute promyelocytic leukaemia treated with arsenic tri-oxide. Br J Haematol 2001,113(1 ):257-8.
39. Singer JW. Cardiac toxicity of arsenic trioxide. Blood 2001 ;98(5): 1633; author reply 1633-4.
40. Li Y, Sun X, Wang L, Zhou Z, Kang YJ. Myocardial toxicity of arsenic trioxide in a mouse model. Cardiovasc Toxicol 2002;2(1):63-73.
41. Shen ZX, Chen GQ, Ni JH, Li XS, Xiong SM, Qiu QY, et al. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): Ⅱ. Clinical efficacy and pharmacokinetics in relapsed patients. Blood 1997; 89(9):3354-60.
42. Zhang TD, Chen GQ, Wang ZG, Wang ZY, Chen SJ, Chen Z. Arsenic trioxide, a therapeutic agent for APL. Oncogene 2001; 20(49):7146-53.
43．张鹏，胡龙虎，周晋，等．二氧化二砷治疗急性早幼粒细胞白血病的机制研究．白血病1996；5(3)：131-133．
44．唐伟，陈国强，史桂英，等．三氧化二砷对急性早幼粒细胞白血病细胞株的双重效应研究．中华医学杂志1997；77(7)：509-511．
45．杜彩文，李德锐，杜英城，等．三氧化二砷诱导人鼻咽低分化鳞癌裸鼠移植瘤细胞分化的研究．癌症2003；22(1)：21-22．
46. Baj G, Arnulfo A, Deaglio S, Mallone R, Vigone A, De Cesaris MG, et al. Arsenic trioxide and breast cancer: analysis of the apoptotic, differentiative and immunomodulatory effects. Breast Cancer Res Treat 2002;73(1):61-73.
47. Siu KP, Chan JY, Fung KP. Effect of arsenic trioxide on human hepatocellular carcinoma HepG2 cells: inhibition of proliferation and induction of apoptosis. Life Sci 2002;71(3):275-85.
48. Oketani M, Kohara K, Tuvdendorj D, Ishitsuka K, Komorizono Y, Ishibashi K, et al. Inhibition by arsenic trioxide of human hepatoma cell growth. Cancer Lett 2002; 183(2): 147-53.
49. Du YH, Ho PC. Arsenic compounds induce cytotoxicity and apoptosis in cisplatin-sensitive and -resistant gynecological cancer cell lines. Cancer Chemother Pharmacol 2001; 47(6): 481-90.
50. Uslu R, Sanli UA, Sezgin C, Karabulut B, Terzioglu E, Omay SB, et al. Arsenic trioxide-mediated cytotoxicity and apoptosis in prostate and ovarian carcinoma cell lines. Clin Cancer Res 2000;6(12):4957-64.
51. Ora I, Bondesson L, Jonsson C, Ljungberg J, Porn-Ares I, Garwicz S, et al. Arsenic trioxide inhibits neuroblastoma growth in vivo and promotes apoptotic cell death in vitro. Biochem Biophys Res Commun 2000;277(1):179-85.
52. Xie D, Yin S, Ou Y, Bai H, Ding F, Wang X, et al. Arsenic trioxide (As(2)O(3)) induced apoptosis and its mechanisms in a human esophageal squamous carcinoma cell line. Chin Med J (Engl) 2002;115(2):280-5.
53. Seol JG, Park WH, Kim ES, Jung CW, Hyun JM, Kim BK, et al. Effect of arsenic trioxide on cell cycle arrest in head and neck cancer cell line PCI-1. Biochem Biophys Res Commun 1999;265(2):400-4.
54. Seol JG, Park WH, Kim ES, Jung CW, Hyun JM, Lee YY, et al. Potential role of caspase-3 and -9 in arsenic trioxide-mediated apoptosis in PCI-1 head and neck cancer cells. Int J Oncol 2001;18(2):249-55.
55. Li X, Ding X, Adrian TE. Arsenic trioxide inhibits proliferation and induces apoptosis in pancreatic cancer cells. Anticancer Res 2002;22(4):2205-13.
56. Karasuiu HY, Karabulut B, Kantarci G, Ozguney I, Sezgin C, Sanli UA, et al. Preparation of arsenic trioxide-loaded microemulsion and its enhanced cytotoxicity on MCF-7 breast carcinoma cell line. Drug Deliv 2004;11(6):345-50.
57. Kanzawa T, Kondo Y, Ito H, Kondo S, Germano I. Induction of autophagic cell death in malignant glioma cells by arsenic trioxide. Cancer Res 2003;63(9):2103-8.
58. Zheng J, Deng YP, Lin C, Fu M, Xiao PG, Wu M. Arsenic trioxide induces apoptosis of HPV16 DNA-immortalized human cervical epithelial cells and selectively inhibits viral gene expression. Int J Cancer 1999; 82:286-92.
59. Liu F, Jan KY. DNA damage in arsenite- and cadmium-treated bovine aortic endothelial cells. Free Radic Biol Med 2000;28(1):55-63.
60. Lew YS, Brown SL, Griffin RJ, Song CW, Kim JH. Arsenic trioxide causes selective necrosis in solid murine tumors by vascular shutdown. Cancer Res 1999;59(24):6033-7.
61. Kito M, Akao Y, Ohishi N, Yagi K, Nozawa Y. Arsenic trioxide-induced apoptosis and its enhancement by buthionine sulfoximine in hepatocellular carcinoma cell lines. Biochem Biophys Res Commun 2002;291(4):861-7.
62．邓志华，蔡洪培，李石，等．三氧化二砷对正常肝细胞及肝癌细胞株的影响．中华消化杂志 1999；19(4)：227-229(4)：227．
63. Shen ZY, Shen WY, Chen MH, Shen J, Cai W J, Zeng Y. Mitochondria, calcium and nitric oxide in the apoptotic pathway of esophageal carcinoma cells induced by As2O3. Int J Mol Med 2002;9(4):385-90.
64. Jiang XH, Wong BC, Yuen ST, Jiang SH, Cho CH, Lai KC, et al. Arsenic trioxide induces apoptosis in human gastric cancer cells through up-regulation of p53 and activation of caspase-3. Int J Cancer 2001; 91 (2): 173-9.
65. Woo SH, Park IC, Park MJ, Lee HC, Lee SJ, Chun YJ, et al. Arsenic trioxide induces apoptosis through a reactive oxygen species-dependent pathway and loss of mitochondrial membrane potential in HeLa cells. Int J Oncol 2002;21(1): 57-63.
66. Um SJ, Lee SY, Kim EJ, Myoung J, Namkoong SE, Park JS. Down-regulation of human papillomavirus E6/E7 oncogene by arsenic trioxide in cervical carcinoma cells. Cancer Lett 2002;181(1):11-22.
67．邓友平，林晨，梁萧，等．三氧化二砷诱导人宫颈癌Hela细胞凋亡及Bcl-2保护作用的机制研究．中国科学1999；29(3)：33．
68．黄守国，孔北华，杨瑞芳，等．三氧化二砷抑制人卵巢癌裸鼠腹腔转移瘤的形成及其机制的初步研究．癌症2002；21(4)：401．
69. Li X, Ding X, Adrian TE. Arsenic trioxide causes redistribution of cell cycle, caspase activation, and GADD expression in human colonic, breast, and pancreatic cancer cells. Cancer Invest 2004;22(3):389-400.
70．陈其奎，袁世珍，黄志清．三氧化二砷诱导胰腺癌细胞周期阻滞与凋亡作用．中华医学杂志 1998；78(8)：578．
71. Nakagawa Y, Akao Y, Morikawa H, Hirata I, Katsu K, Naoe T, et al. Arsenic trioxide-induced apoptosis through oxidative stress in cells of colon cancer cell lines. Life Sci 2002;70 (19):2253-69.
72. Ramirez P, Eastmond DA, Laclette JP, Ostrosky-Wegman P. Disruption of microtubule assembly and spindle formation as a mechanism for the induction of aneuploid cells by sodium arsenite and vanadium pentoxide. Mutat Res 1997;386(3):291-8.
73. Li YM, Broome JD. Arsenic targets tubulins to induce apoptosis in myeloid leukemia cells. Cancer Res 1999;59(4):776-80.
74. Larochette N, Decaudin D, Jacotot E, Brenner C, Marzo I, Susin SA, et al. Arsenite induces apoptosis via a direct effect on the mitochondrial permeability transition pore. Exp Cell Res 1999;249(2):413-21.
75. Chen YC, Lin-Shiau SY, Lin JK. Involvement of reactive oxygen species and caspase 3 activation in arsenite-induced apoptosis. J Cell Physiol 1998;177(2):324-33.
76. Huang C, Bode AM, Chen NY, Ma WY, Li J, Nomura M, et al. Transactivation of AP-1 in AP-1-luciferase reporter transgenic mice by arsenite and arsenate. Anticancer Res 2001;21(1A):261-7.
77. Liu J, Kadiiska MB, Liu Y, Lu T, Qu W, Waalkes MP. Stress-related gene expression in mice treated with inorganic arsenicals. Toxicol Sci 2001;61(2):314-20.
78. Mathas S, Lietz A, Janz M, Hinz M, Jundt F, Scheidereit C, et al. Inhibition of NF-kappaB essentially contributes to arsenic-induced apoptosis. Blood 2003; 102(3): 1028-34.
79. Cavigelli M, Li WW, Lin A, Su B, Yoshioka K, Karin M. The tumor promoter arsenite stimulates AP-1 activity by inhibiting a JNK Phosphatase. EMBO J 1996;15(22):6269-79.
80. Huang C, Ma WY, Li J, Dong Z. Arsenic induces apoptosis through a c-Jun NH2-terminal kinase-dependent, p53-independent pathway. Cancer Res 1999;59(13):3053-8.
81. Porter AC, Fanger GR, Vaillancourt RR. Signal transduction pathways regulated by arsenate and arsenite. Oncogene 1999; 18(54):7794-802.
82. Simeonova PP, Wang S, Toriuma W, Kommineni V, Matheson J, Unimye N, et al. Arsenic mediates cell proliferation and gene expression in the bladder epithelium: association with activating protein-1 transactivation. Cancer Res 2000;60(13):3445-53.
83. Klingler K, Tchou-Wong KM, Brandli O, Aston C, Kim R, Chi C, et al. Effects of mycobacteria on regulation of apoptosis in mononuclear phagocytes. Infect Immun 1997;65(12):5272-8.
84. Shay JW, Bacchetti S. A survey of telomerase activity in human cancer. Eur J Cancer 1997;33(5):787-91.
85．任玮玮．李弘，张恒．三氧化二砷对肝癌Bel-7402细胞生长及端粒酶活性的影响．暨南大学学报2003；24：25-29．
86．樊华，俞军．三氧化二砷对鼠移植性肝癌端粒酶活性的影响．中国临床医学2002；9：121-123．
87．王南瑶，刘琳，邱少敏，等．三氧化二砷对人结肠癌裸鼠移植瘤端粒酶活性及其催化亚单位表达的影响．东南大学学报：医学版2005；24(3)：168—170．
88．章尧，赵燕，陈昌杰，等．三氧化二砷对HL-60细胞凋亡及其端粒酶hTERTmRNA表达影响的实验研究．中国药理学通报2003；19(2)：206-208．
1. Cervical cancer. NIH Consens Statement 1996; 14:1-38; quiz 4p.
2. Lazo PA. The molecular genetics of cervical carcinoma. Br J Cancer 1999; 80:2008-18.
3. Vernhet L, Allain N, Le Vee M, Morel F, Guillouzo A, Fardel O. Blockage of multidrug resistance-associated proteins potentiates the inhibitory effects of arsenic trioxide on CYP1A1 induction by polycyclic aromatic hydrocarbons. J Pharmacol Exp Ther 2003; 304:145-55.
4. Wei LH, Lai KP, Chen CA, Cheng CH, Huang YJ, Chou CH, Kuo ML, Hsieh CY. Arsenic trioxide prevents radiation-enhanced tumor invasiveness and inhibits matrix metalloproteinase-9 through downregulation of nuclear factor kappaB. Oncogene 2005; 24:390-8.
5. Zheng J, Deng YP, Lin C, Fu M, Xiao PG, Wu M. Arsenic trioxide induces apoptosis of HPV16 DNA-immortalized human cervical epithelial cells and selectively inhibits viral gene expression. Int J Cancer 1999; 82:286-92.
6. Tong T, Ji J, Jin S, Li X, Fan W, Song Y, Wang M, Liu Z, Wu M, Zhan Q. Gadd45a expression induces Bim dissociation from the cytoskeleton and translocation to mitochondria. Molecular and cellular biology 2005; 25:4488-500.
7. Makin GW, Corfe BM, Griffiths GJ, Thistlethwaite A, Hickman JA, Dive C. Damage-induced Bax N-terminal change, translocation to mitochondria and formation of Bax dimers/complexes occur regardless of cell fate. Embo J 2001; 20:6306-15.
8. Alley MC, Scudiero DA, Monks A, Hursey ML, Czerwinski MJ, Fine DL, Abbott BJ, Mayo JG, Shoemaker RH, Boyd MR. Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. Cancer Res 1988; 48:589-601.
9. Antonsson B, Montessuit S, Sanchez B, Martinou JC. Bax is present as a high molecular weight oligomer/complex in the mitochondrial membrane of apoptotic cells. J Biol Chem 2001; 276:11615-23.
10.Banerjee J, Ghosh S. Bax increases the pore size of rat brain mitochondrial voltage-dependent anion channel in the presence of tBid. Biochem Biophys Res Commun 2004; 323:310-4.
11.Scheffner M, Werness BA, Huibregtse JM, Levine AJ, Howley PM. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 1990; 63:1129-36.
12.Giafis N, Katsoulidis E, Sassano A, Tallman MS, Higgins LS, Nebreda AR, Davis RJ, Platanias LC. Role of the p38 mitogen-activated protein kinase pathway in the generation of arsenic trioxide-dependent cellular responses. Cancer Res 2006; 66:6763-71.
13.Kastan MB, Zhan Q, el-Deiry WS, Carrier F, Jacks T, Walsh WV, Plunkett BS, Vogelstein B, Fornace AJ, Jr. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell 1992; 71:587-97.
14.Takekawa M, Saito H. A family of stress-inducible GADD45-like proteins mediate activation of the stress-responsive MTK1/MEKK4 MAPKKK. Cell 1998;95:521-30.
15.Sugiyama T, Shimizu S, Matsuoka Y, Yoneda Y, Tsujimoto Y. Activation of mitochondrial voltage-dependent anion channel by apro-apoptotic BH3-only protein Bim. Oncogene 2002; 21:4944-56.
16.Hockenbery DM, Oltvai ZN, Yin XM, Milliman CL, Korsmeyer SJ. Bcl-2 functions in an antioxidant pathway to prevent apoptosis. Cell 1993; 75:241-51.
17.Voehringer DW, Meyn RE. Redox aspects of Bcl-2 function. Antioxid Redox Signal 2000; 2:537-50.
18. Ling YH, Jiang JD, Holland JF, Perez-Soler R. Arsenic trioxide produces polymerization of microtubules and mitotic arrest before apoptosis in human tumor cell lines. Mol Pharmacol 2002; 62:529-38.
19.Grad JM, Cepero E, Boise LH. Mitochondria as targets for established and novel anti-cancer agents. Drug Resist Updat 2001; 4:85-91.
20. Huibregtse JM, Scheffner M, Howley PM. Localization of the E6-AP regions that direct human papillomavirus E6 binding, association with p53, and ubiquitination of associated proteins. Molecular and cellular biology 1993; 13:4918-27.
21.Hildesheim J, Bulavin DV, Anver MR, Alvord WG, Hollander MC, Vardanian L, Fornace AJ, Jr. Gadd45a protects against UV irradiation-induced skin tumors, and promotes apoptosis and stress signaling via MAPK and p53. Cancer Res 2002;62:7305-15.
1. Cervical cancer. NIH Consens Statement 1996; 14:1-38; quiz 4p.
2. Lazo PA. The molecular genetics of cervical carcinoma. Br J Cancer 1999; 80:2008-18.
3. zur Hausen H. Intracellular surveillance of persisting viral infections. Human genital cancer results from deficient cellular control of papillomavirus gene expression. Lancet 1986; 2:489-91.
4. zur Hausen H. Papillomaviruses in anogenital cancer as a model to understand the role of viruses in human cancers. Cancer Res 1989; 49:4677-81.
5. Uslu R, Sanli UA, Sezgin C, Karabulut B, Terzioglu E, Omay SB, Goker E. Arsenic trioxide-mediated cytotoxicity and apoptosis in prostate and ovarian carcinoma cell lines. Clin Cancer Res 2000; 6:4957-64.
6. Shen ZY, Shen J, Cai WJ, Hong C, Zheng MH. The alteration of mitochondria is an early event of arsenic trioxide induced apoptosis in esophageal carcinoma cells. Int J Mol Med 2000; 5:155-8.
7. Maeda H, Hori S, Nishitoh H, Ichijo H, Ogawa O, Kakehi Y, Kakizuka A. Tumor growth inhibition by arsenic trioxide (As2O3) in the orthotopic metastasis model of androgen-independent prostate cancer. Cancer Res 2001; 61:5432-40.
8. Zheng J, Deng YP, Lin C, Fu M, Xiao PG, Wu M. Arsenic trioxide induces apoptosis of HPV16 DNA-immortalized human cervical epithelial cells and selectively inhibits viral gene expression. Int J Cancer 1999; 82:286-92.
9. Jing Yu HQ, Yunfeng Li, Yang Wang, Xueyan Zhang, Xiao Liang, Ming Fu and Chen Lin. Therapeutic Effect of Arsenic Trioxide (As2O3) on Cervical Cancer in Vitro and in Vivo through Apoptosis Induction cancer biology and therapy 2007; 6.
10.Vleminckx K, Vakaet L, Jr., Mareel M, Fiers W, van Roy F. Genetic manipulation of E-cadherin expression by epithelial tumor cells reveals an invasion suppressor role. Cell 1991; 66:107-19.
11. Williams TM, Lisanti MR The caveolin proteins. Genome biology 2004; 5:214.
12.Capozza F, Williams TM, Schubert W, McClain S, Bouzahzah B, Sotgia F, Lisanti MR Absence of caveolin-1 sensitizes mouse skin to carcinogen-induced epidermal hyperplasia and tumor formation. The American journal of pathology 2003; 162:2029-39.
13. Park DS, Lee H, Frank PG, Razani B, Nguyen AV, Parlow AF, Russell RG, Hulit J, Pestell RG, Lisanti MR Caveolin-1-deficient mice show accelerated mammary gland development during pregnancy, premature lactation, and hyperactivation of the Jak-2/STAT5a signaling cascade. Molecular biology of the cell 2002; 13:3416-30.
14.Wei LH, Lai KP, Chen CA, Cheng CH, Huang YJ, Chou CH, Kuo ML, Hsieh CY. Arsenic trioxide prevents radiation-enhanced tumor invasiveness and inhibits matrix metalloproteinase-9 through downregulation of nuclear factor kappaB. Oncogene 2005; 24:390-8.
15. Li HP, Chang YS. Epstein-Barr virus latent membrane protein 1: structure and functions. Journal of biomedical science 2003; 10:490-504.
16.Rimm DL, Koslov ER, Kebriaei P, Cianci CD, Morrow JS. Alpha 1(E)-catenin is an actin-binding and -bundling protein mediating the attachment of F-actin to the membrane adhesion complex. Proceedings of the National Academy of Sciences of the United States of America 1995; 92:8813-7.
17.Vasioukhin V, Fuchs E. Actin dynamics and cell-cell adhesion in epithelia. Current opinion in cell biology 2001; 13:76-84.
18.Morin PJ. beta-catenin signaling and cancer. Bioessays 1999; 21:1021-30.
19.Peifer M, Polakis P. Wnt signaling in oncogenesis and embryogenesis-a look outside the nucleus. Science 2000; 287:1606-9.
20.Bagnoli M, Tomassetti A, Figini M, Flati S, Dolo V, Canevari S, Miotti S. Downmodulation of caveolin-1 expression in human ovarian carcinoma is directly related to alpha-folate receptor overexpression. Oncogene 2000; 19:4754-63.
21. Bender FC, Reymond MA, Bron C, Quest AR Caveolin-1 levels are down-regulated in human colon tumors, and ectopic expression of caveolin-1 in colon carcinoma cell lines reduces cell tumorigenicity. Cancer research 2000; 60:5870-8.
22.Wiechen K, Sers C, Agoulnik A, Arlt K, Dietel M, Schlag PM, Schneider U. Down-regulation of caveolin-1, a candidate tumor suppressor gene, in sarcomas. The American journal of pathology 2001; 158:833-9.
23. Racine C, Belanger M, Hirabayashi H, Boucher M, Chakir J, Couet J. Reduction of caveolin 1 gene expression in lung carcinoma cell lines. Biochemical and biophysical research communications 1999; 255:580-6.
24. Barnes PJ, Karin M. Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. The New England journal of medicine 1997; 336:1066-71.
25. Baldwin AS, Jr. The NF-kappa B and I kappa B proteins: new discoveries and insights. Annual review of immunology 1996; 14:649-83.
26. Rossi A, Kapahi P, Natoli G, Takahashi T, Chen Y, Karin M, Santoro MG. Anti-inflammatory cyclopentenone prostaglandins are direct inhibitors of IkappaB kinase. Nature 2000; 403:103-8.
27. Karin M, Ben-Neriah Y. Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity. Annual review of immunology 2000; 18:621-63.
28. Kapahi P, Takahashi T, Natoli G, Adams SR, Chen Y, Tsien RY, Karin M. Inhibition of NF-kappa B activation by arsenite through reaction with a critical cysteine in the activation loop of Ikappa B kinase. The Journal of biological chemistry 2000; 275:36062-6.
29.Kuphal S, Poser I, Jobin C, Hellerbrand C, Bosserhoff AK. Loss of E-cadherin leads to upregulation of NFkappaB activity in malignant melanoma. Oncogene 2004; 23:8509-19.
30. Lo AK, Huang DP, Lo KW, Chui YL, Li HM, Pang JC, Tsao SW. Phenotypic alterations induced by the Hong Kong-prevalent Epstein-Barr virus-encoded LMP1 variant (2117-LMP1)in nasopharyngeal epithelial cells. International journal of cancer 2004; 109:919-25.
1. Einstein MH, Goldberg GL. Human papillomavirus and cervical neoplasia. Cancer Invest, 2002, 20 (7-8): 1080-1085
2. Dell G, Gaston K. Human papillomaviruses and their role in cervical cancer. Cell Mol Life Sci, 2001, 58 12-13): 1923-1942
3. Sherr CJ. Cancer cell cycles. Science, 1996, 274 (5293): 1672-1677
4. Khleif SN, DeGregori J, Yee CL, et al. Inhibition of cyclinD-CDK4/ CDK6 activity is associated with an E2F-mediated induction of cyclin kinase inhibitor activity. Proc Natl Acad Sci USA, 1996, 93 (9): 4350-4354
5. Murphy N, Ring M, Killalea AG, et al. p16~(INK4A) as a marker for cervical dyskaryosis: CIN and cGIN in cervical biopsies and ThinPrepsmears. J Clin Pathol, 2003,56 (1 ) :56-63
6. Kanao H, Enomoto T, Ueda Y, et al. Correlation between p14/p16~(INK4A) expression and HPV infection in uterine cervical cancer. Cancer Lett, 2004, 213(1): 31-37
7. Kalof AN, Evans MF, Simmons-Arnold L, et al. p16~(INK4A) immunoexpression and HPV in situ hybridization signal patterns: potential markers of high-grade cervical intraepithelial neoplasia. Am J Surg Pathol, 2005, 29 (5):674-679
8. Schorge JO, Lea KS, Elias KJ, et al. p16 as a molecular biomarker of cervical adenocarcinoma. Am J Obstet Gynecol, 2004, 190 (3):668-673
9. Lovec H, Sewing A, Lucibello FC, et al. Oncogenic activity of CyclinD1 revealed through cooperation with Ha2ras link between cell cycle control and malignant transformation. Oncogene, 1994, 9 (1): 3232326
10. Xiong Y, Connolly T, Fucher B, et al. Human D type cyclin. Cell, 1991,65:6911
11. Kato J.Matsushime H.Hiebert sw, et al. Direct binding of CyclinD to the retinoblastoma gene product (pRb) and pRb phosphorylation by the Cyclin D - dependent kinase cdk4. Genes Dev , 1993 ,7 :3311
12. Sheer CJ. G1 phase progression: cycling on cue. Cell, 1994 ,79 : 5511
13. Hosokawa Y.Arnold A. CyclinD1/ PRAD1 as a central target in oncogenesis. J Lab Clin Med, 1996,127 (3) 2461
14. Hall P A, Levison D A, Woods A L, et al. Proliferating cell nuclear antigen ( PCNA) immunolocalization in paraffin section :an index of cell proliferation with evidence of deregulated expression in somme neoplasms. J Pathol, 1990,162:285-294.
15. Woods A L, Hall P A .Shepherd N A, et al. The assessment of Proliferating cell nuclear antigen ( PCNA) immunostaining inprimary gast rointestinal lymphomas and it s relationship to histologycal grade ,S + G2 + M phase fraction (flow cytometric analysis) and prognosis. Histopathology, 1991, 19:21 -27.
16. Hiroyuki Miki MD, Hirotaka Yamada, Keiji Mitamura. Involvement p38 MAPK in apoptotic and proliferative alteration in human colorectal cancers. Anticancer Research, 1999,19 :5283 - 5292.
17. Lee C S. Differences in cell proliferation and prognostic significance of proliferation cell nuclear antigen and ki-67 antigen immunoreactivity in insitu and invasive carcinomas of the extrahepatic biliary tract. Cancer, 1996 , 78:1881-1887.
18. Thomas H, Nasim M M, Sarraf C E, et al. Proliferating cell nuclear antigen ( PCNA ) immunostiaining a prognostic factor in ovarian cancer ? Br J Cancer, 1995,71 :357 - 362.
19. Oya M, Yao T, Nagai E, et al. Metastasizing int ramucosal gastric carcinomas , well differentiatieal type and proliferative activity using proliferative cell nuclear antigen and ki267. Cancer, 1995 , 75 :926 - 935.
20. D Errico A, Garbisa S , Liotta L A, et al. Augmentation of type IV Collagenase , Lamini receptor, and ki267 proliferation antigen associated with human colon , gastric, and breast carcinoma progression. Mod Patho, 1991, 4 :239 - 246.
21. Hess J, Angel P, Schorpp- Kistner M. AP- 1 subunits: quarrel and harmony among siblings. J Cell Sci, 2004, 117(Pt 25):5 965
22. Fujioka S, Niu J, Schmidt C, et al. NF- κb and AP-1 connection: mechanism of NF- κB dependent regulation of AP-1 activity. Mol Cell Biol, 2004,24(17):7 806
23. Jiang X H , Wong B C , Lin M C ,et al. Functional p53 is required for triptolide induced apoptosis and AP-1 and nuclear factor-kappaB activation in gastric cancer cells. Oncogene, 2001, 20 (55):8009 - 8018.
24. Stein B, Baldwin A S, Ballard D W, et al. Cross-coupling of the NF-kappa B p65 and Fos /Jun transcription factors produces potentiated biological function. EMBO J, 1993, 12 (10) :3879- 3991.
25. Li J J, Westergaard C, Ghosh P, et al. Inhibitors of both nuclear factor-kappaB and activator protein-1 activation block the neoplastic transformation response. Cancer Res, 1997, 57( 16): 3569- 3576.
2. Y L Kwong, D Todd. Delicious poison:Arsenic trioxide for the treatment of leukemia. Blood 1997;89(9):3487.
3. Waxman S, Anderson KC. History of the development of arsenic derivatives in cancer therapy. Oncologist 2001 ;6 Suppl 2:3-10.
4. Gallagher RE. Arsenic--new life for an old potion. N Engl J Med 1998;339 (19): 1389-91.
5. Novick SC, Warrell RP Jr. Arsenicals in hematologic cancers. Semin Oncol 2000;27(5): 495-501.
6. Snow ET. Metal carcinogenesis: mechanistic implications. Pharmacol Ther 1992;53(1): 31-65.
7. Zhao CQ, Young MR, Diwan BA, Coogan TP, Waalkes MP. Association of arsenic-induced malignant transformation with DNA hypomethylation and aberrant gene expression. Proc Natl Acad Sci U S A 1997;94(20): 10907-12.
8. Goering PL, Aposhian HV, Mass MJ, Cebrian M, Beck BD, Waalkes MP. The enigma of arsenic carcinogenesis: role of metabolism. Toxicol Sci 1999;49 (1):5-14.
9. Hei TK, Liu SX, Waldren C. Mutagenicity of arsenic in mammalian cells: role of reactive oxygen species. Proc Natl Acad Sci U S A 1998;95(14):8103-7.
10. Chen H, Liu J, Merrick BA, Waalkes MP. Genetic events associated with arsenic-induced malignant transformation: applications of cDNA microarray technology. Mol Carcinog 2001 ;30 (2):79-87.
11. Wang TS, Shu YF, Liu YC, Jan KY, Huang H. Glutathione peroxidase and catalase modulate the genotoxicity of arsenite. Toxicology 1997; 121(3): 229-37.
12. Zhang P, Wang S, Hu L, Qiu F, Yang H, Xiao Y, et al. [Seven years' summary report on the treatment of acute promyelocytic leukemia with arsenic trioxide—an analysis of 242 cases]. Zhonghua Xue Ye Xue Za Zhi 2000;21(2):67-70.
13．孙鸿德，马玲，胡晓晨，等．癌灵Ⅰ号结合中西医辩证治疗急性早幼粒白血病32例．中国中西医结合杂志1992：12(3)：170-171．
14．张鹏，王树叶，胡龙虎，等．三氧化二砷注射液治疗72例急性早幼粒细胞白血病．中华血液学杂志1996；17(2)：58-61．
15. Chen GQ, Zhu J, Shi XG, et al. In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia: As2O3 induce NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RARalpha/PML proteins.Blood 1996,88:1052
16. Mervis J. Ancient remedy performs new tricks. Science 1996;273(5275):578.
17. Soignet SL, Maslak P, Wang ZG, Jhanwar S, Calleja E, Dardashti LJ, et al. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med 1998;339(19):1341-8.
18．张春，胡晓晨，赵晓刚．亚砷酸注射液治疗慢性粒细胞白血病．中国中医药信息杂志2003；10(3)：51．
19. Vey N. Arsenic trioxide for the treatment of myelodysplastic syndromes. Expert Opin Pharmacother 2004;5(3):613-21.
20. Bahlis NJ, McCafferty-Grad J, Jordan-McMurry I, Neil J, Reis I, Kharfan-Dabaja M, et al. Feasibility and correlates of arsenic trioxide combined with ascorbic acid-mediated depletion of intracellular glutathione for the treatment of relapsed/refractory multiple myeloma. Clin Cancer Res 2002;8(12):3658-68.
21．孟秀琴，艾工文．18例多发性骨髓瘤临床分析．临床血液学杂志2005；18(1)：40-41．
22．钱军，秦叔逵，何泽明．三氧化二砷注射液治疗中晚期原发性肝胆癌的临床研究．中华肿瘤杂志2001；23(6)：487．
23．项颖，黄风鸣．三氧化二砷注射液治疗中晚期原发性肝癌16例报告．临床肿瘤学杂志2003；8(1)：36—37．
24．朱安龙，刘连新，朴大勋，等．应用二氧化二砷连续区域化疗治疗肝癌．中华肝胆外科杂志2003；9(4)：205—206．
25．宋建功，贾利敏，孔东亮．经胃镜局部注射砷剂治疗中晚期食管癌临床研究．中国医学理论与实践2002；4：434．
26．竺涵光，王跃平，张志远，等．三氧化二砷经导管动脉介入治疗口腔鳞癌(附3例报告)．口腔医学纵横杂志2000；16(1)：35—36．
27．秦叔逵，钱军，何泽民，等．三氧化二砷注射液治疗晚期胆囊癌．临床肿瘤学杂志2000；5(4)：286—287．
28．郑作深，饶健．亚砷酸注射液治疗盲肠癌术后复发获完全缓解一例．临床肿瘤学杂志2001；6(4)：37．
29. Vuky J, Yu R, Schwartz L, Motzer RJ. Phase Ⅱ trial of arsenic trioxide in patients with metastatic renal cell carcinoma. Invest New Drugs 2002;20(3):327-30.
30. Dalton WS. Targeting the mitochondria: an exciting new approach to myeloma therapy. Commentary re: N. J. Bahlis et al, Feasibility and correlates of arsenic trioxide combined with ascorbic acid-mediated depletion of intracellular glutathione for the treatment of relapsed/refractory multiple myeloma. Clin. Cancer Res, 8: 3658-3668, 2002. Clin Cancer Res 2002;8(12):3643-5.
31. Ohnishi K, Yoshida H, Shigeno K, Nakamura S, Fujisawa S, Naito K, et al. Arsenic trioxide therapy for relapsed or refractory Japanese patients with acute promyelocytic leukemia: need for careful electrocardiogram monitoring. Leukemia 2002; 16(4):617-22.
32. Soignet SL, Frankel SR, Douer D, Tallman MS, Kantarjian H, Calleja E, et al. United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol 2001 ;19(18):3852-60.
33. Ohnishi K, Yoshida H, Shigeno K, Nakamura S, Fujisawa S, Naito K, et al. Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia. Ann Intern Med 2000;133(11):881-5.
34. Barbey JT, Soignet S. Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia. Ann Intern Med 2001;135(9):842-3.
35. Huang SY, Chang CS, Tang JL, Tien HF, Kuo TL, Huang SF, et al. Acute and chronic arsenic poisoning associated with treatment of acute promyelocytic leukaemia. Br J Haematol 1998; 103(4): 1092-5.
36. Camacho LH, Soignet SL, Chanel S, Ho R, Heller G, Scheinberg DA, et al. Leukocytosis and the retinoic acid syndrome in patients with acute promyelocytic leukemia treated with arsenic trioxide. J Clin Oncol 2000;18(13):2620-5.
37. Roberts TF, Sprague K, Schenkein D, Miller KB, Relias V. Hyperleukocytosis during induction therapy with arsenic trioxide for relapsed acute promyelocytic leukemia associated with central nervous system infarction. Blood 2000;96(12):4000-1.
38. Mathews V, Balasubramanian P, Shaji RV, George B, Chandy M, Srivastava A. Central nervous system relapse in a patient with acute promyelocytic leukaemia treated with arsenic tri-oxide. Br J Haematol 2001,113(1 ):257-8.
39. Singer JW. Cardiac toxicity of arsenic trioxide. Blood 2001 ;98(5): 1633; author reply 1633-4.
40. Li Y, Sun X, Wang L, Zhou Z, Kang YJ. Myocardial toxicity of arsenic trioxide in a mouse model. Cardiovasc Toxicol 2002;2(1):63-73.
41. Shen ZX, Chen GQ, Ni JH, Li XS, Xiong SM, Qiu QY, et al. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): Ⅱ. Clinical efficacy and pharmacokinetics in relapsed patients. Blood 1997; 89(9):3354-60.
42. Zhang TD, Chen GQ, Wang ZG, Wang ZY, Chen SJ, Chen Z. Arsenic trioxide, a therapeutic agent for APL. Oncogene 2001; 20(49):7146-53.
43．张鹏，胡龙虎，周晋，等．二氧化二砷治疗急性早幼粒细胞白血病的机制研究．白血病1996；5(3)：131-133．
44．唐伟，陈国强，史桂英，等．三氧化二砷对急性早幼粒细胞白血病细胞株的双重效应研究．中华医学杂志1997；77(7)：509-511．
45．杜彩文，李德锐，杜英城，等．三氧化二砷诱导人鼻咽低分化鳞癌裸鼠移植瘤细胞分化的研究．癌症2003；22(1)：21-22．
46. Baj G, Arnulfo A, Deaglio S, Mallone R, Vigone A, De Cesaris MG, et al. Arsenic trioxide and breast cancer: analysis of the apoptotic, differentiative and immunomodulatory effects. Breast Cancer Res Treat 2002;73(1):61-73.
47. Siu KP, Chan JY, Fung KP. Effect of arsenic trioxide on human hepatocellular carcinoma HepG2 cells: inhibition of proliferation and induction of apoptosis. Life Sci 2002;71(3):275-85.
48. Oketani M, Kohara K, Tuvdendorj D, Ishitsuka K, Komorizono Y, Ishibashi K, et al. Inhibition by arsenic trioxide of human hepatoma cell growth. Cancer Lett 2002; 183(2): 147-53.
49. Du YH, Ho PC. Arsenic compounds induce cytotoxicity and apoptosis in cisplatin-sensitive and -resistant gynecological cancer cell lines. Cancer Chemother Pharmacol 2001; 47(6): 481-90.
50. Uslu R, Sanli UA, Sezgin C, Karabulut B, Terzioglu E, Omay SB, et al. Arsenic trioxide-mediated cytotoxicity and apoptosis in prostate and ovarian carcinoma cell lines. Clin Cancer Res 2000;6(12):4957-64.
51. Ora I, Bondesson L, Jonsson C, Ljungberg J, Porn-Ares I, Garwicz S, et al. Arsenic trioxide inhibits neuroblastoma growth in vivo and promotes apoptotic cell death in vitro. Biochem Biophys Res Commun 2000;277(1):179-85.
52. Xie D, Yin S, Ou Y, Bai H, Ding F, Wang X, et al. Arsenic trioxide (As(2)O(3)) induced apoptosis and its mechanisms in a human esophageal squamous carcinoma cell line. Chin Med J (Engl) 2002;115(2):280-5.
53. Seol JG, Park WH, Kim ES, Jung CW, Hyun JM, Kim BK, et al. Effect of arsenic trioxide on cell cycle arrest in head and neck cancer cell line PCI-1. Biochem Biophys Res Commun 1999;265(2):400-4.
54. Seol JG, Park WH, Kim ES, Jung CW, Hyun JM, Lee YY, et al. Potential role of caspase-3 and -9 in arsenic trioxide-mediated apoptosis in PCI-1 head and neck cancer cells. Int J Oncol 2001;18(2):249-55.
55. Li X, Ding X, Adrian TE. Arsenic trioxide inhibits proliferation and induces apoptosis in pancreatic cancer cells. Anticancer Res 2002;22(4):2205-13.
56. Karasuiu HY, Karabulut B, Kantarci G, Ozguney I, Sezgin C, Sanli UA, et al. Preparation of arsenic trioxide-loaded microemulsion and its enhanced cytotoxicity on MCF-7 breast carcinoma cell line. Drug Deliv 2004;11(6):345-50.
57. Kanzawa T, Kondo Y, Ito H, Kondo S, Germano I. Induction of autophagic cell death in malignant glioma cells by arsenic trioxide. Cancer Res 2003;63(9):2103-8.
58. Zheng J, Deng YP, Lin C, Fu M, Xiao PG, Wu M. Arsenic trioxide induces apoptosis of HPV16 DNA-immortalized human cervical epithelial cells and selectively inhibits viral gene expression. Int J Cancer 1999; 82:286-92.
59. Liu F, Jan KY. DNA damage in arsenite- and cadmium-treated bovine aortic endothelial cells. Free Radic Biol Med 2000;28(1):55-63.
60. Lew YS, Brown SL, Griffin RJ, Song CW, Kim JH. Arsenic trioxide causes selective necrosis in solid murine tumors by vascular shutdown. Cancer Res 1999;59(24):6033-7.
61. Kito M, Akao Y, Ohishi N, Yagi K, Nozawa Y. Arsenic trioxide-induced apoptosis and its enhancement by buthionine sulfoximine in hepatocellular carcinoma cell lines. Biochem Biophys Res Commun 2002;291(4):861-7.
62．邓志华，蔡洪培，李石，等．三氧化二砷对正常肝细胞及肝癌细胞株的影响．中华消化杂志 1999；19(4)：227-229(4)：227．
63. Shen ZY, Shen WY, Chen MH, Shen J, Cai W J, Zeng Y. Mitochondria, calcium and nitric oxide in the apoptotic pathway of esophageal carcinoma cells induced by As2O3. Int J Mol Med 2002;9(4):385-90.
64. Jiang XH, Wong BC, Yuen ST, Jiang SH, Cho CH, Lai KC, et al. Arsenic trioxide induces apoptosis in human gastric cancer cells through up-regulation of p53 and activation of caspase-3. Int J Cancer 2001; 91 (2): 173-9.
65. Woo SH, Park IC, Park MJ, Lee HC, Lee SJ, Chun YJ, et al. Arsenic trioxide induces apoptosis through a reactive oxygen species-dependent pathway and loss of mitochondrial membrane potential in HeLa cells. Int J Oncol 2002;21(1): 57-63.
66. Um SJ, Lee SY, Kim EJ, Myoung J, Namkoong SE, Park JS. Down-regulation of human papillomavirus E6/E7 oncogene by arsenic trioxide in cervical carcinoma cells. Cancer Lett 2002;181(1):11-22.
67．邓友平，林晨，梁萧，等．三氧化二砷诱导人宫颈癌Hela细胞凋亡及Bcl-2保护作用的机制研究．中国科学1999；29(3)：33．
68．黄守国，孔北华，杨瑞芳，等．三氧化二砷抑制人卵巢癌裸鼠腹腔转移瘤的形成及其机制的初步研究．癌症2002；21(4)：401．
69. Li X, Ding X, Adrian TE. Arsenic trioxide causes redistribution of cell cycle, caspase activation, and GADD expression in human colonic, breast, and pancreatic cancer cells. Cancer Invest 2004;22(3):389-400.
70．陈其奎，袁世珍，黄志清．三氧化二砷诱导胰腺癌细胞周期阻滞与凋亡作用．中华医学杂志 1998；78(8)：578．
71. Nakagawa Y, Akao Y, Morikawa H, Hirata I, Katsu K, Naoe T, et al. Arsenic trioxide-induced apoptosis through oxidative stress in cells of colon cancer cell lines. Life Sci 2002;70 (19):2253-69.
72. Ramirez P, Eastmond DA, Laclette JP, Ostrosky-Wegman P. Disruption of microtubule assembly and spindle formation as a mechanism for the induction of aneuploid cells by sodium arsenite and vanadium pentoxide. Mutat Res 1997;386(3):291-8.
73. Li YM, Broome JD. Arsenic targets tubulins to induce apoptosis in myeloid leukemia cells. Cancer Res 1999;59(4):776-80.
74. Larochette N, Decaudin D, Jacotot E, Brenner C, Marzo I, Susin SA, et al. Arsenite induces apoptosis via a direct effect on the mitochondrial permeability transition pore. Exp Cell Res 1999;249(2):413-21.
75. Chen YC, Lin-Shiau SY, Lin JK. Involvement of reactive oxygen species and caspase 3 activation in arsenite-induced apoptosis. J Cell Physiol 1998;177(2):324-33.
76. Huang C, Bode AM, Chen NY, Ma WY, Li J, Nomura M, et al. Transactivation of AP-1 in AP-1-luciferase reporter transgenic mice by arsenite and arsenate. Anticancer Res 2001;21(1A):261-7.
77. Liu J, Kadiiska MB, Liu Y, Lu T, Qu W, Waalkes MP. Stress-related gene expression in mice treated with inorganic arsenicals. Toxicol Sci 2001;61(2):314-20.
78. Mathas S, Lietz A, Janz M, Hinz M, Jundt F, Scheidereit C, et al. Inhibition of NF-kappaB essentially contributes to arsenic-induced apoptosis. Blood 2003; 102(3): 1028-34.
79. Cavigelli M, Li WW, Lin A, Su B, Yoshioka K, Karin M. The tumor promoter arsenite stimulates AP-1 activity by inhibiting a JNK Phosphatase. EMBO J 1996;15(22):6269-79.
80. Huang C, Ma WY, Li J, Dong Z. Arsenic induces apoptosis through a c-Jun NH2-terminal kinase-dependent, p53-independent pathway. Cancer Res 1999;59(13):3053-8.
81. Porter AC, Fanger GR, Vaillancourt RR. Signal transduction pathways regulated by arsenate and arsenite. Oncogene 1999; 18(54):7794-802.
82. Simeonova PP, Wang S, Toriuma W, Kommineni V, Matheson J, Unimye N, et al. Arsenic mediates cell proliferation and gene expression in the bladder epithelium: association with activating protein-1 transactivation. Cancer Res 2000;60(13):3445-53.
83. Klingler K, Tchou-Wong KM, Brandli O, Aston C, Kim R, Chi C, et al. Effects of mycobacteria on regulation of apoptosis in mononuclear phagocytes. Infect Immun 1997;65(12):5272-8.
84. Shay JW, Bacchetti S. A survey of telomerase activity in human cancer. Eur J Cancer 1997;33(5):787-91.
85．任玮玮．李弘，张恒．三氧化二砷对肝癌Bel-7402细胞生长及端粒酶活性的影响．暨南大学学报2003；24：25-29．
86．樊华，俞军．三氧化二砷对鼠移植性肝癌端粒酶活性的影响．中国临床医学2002；9：121-123．
87．王南瑶，刘琳，邱少敏，等．三氧化二砷对人结肠癌裸鼠移植瘤端粒酶活性及其催化亚单位表达的影响．东南大学学报：医学版2005；24(3)：168—170．
88．章尧，赵燕，陈昌杰，等．三氧化二砷对HL-60细胞凋亡及其端粒酶hTERTmRNA表达影响的实验研究．中国药理学通报2003；19(2)：206-208．
1. Cervical cancer. NIH Consens Statement 1996; 14:1-38; quiz 4p.
2. Lazo PA. The molecular genetics of cervical carcinoma. Br J Cancer 1999; 80:2008-18.
3. Vernhet L, Allain N, Le Vee M, Morel F, Guillouzo A, Fardel O. Blockage of multidrug resistance-associated proteins potentiates the inhibitory effects of arsenic trioxide on CYP1A1 induction by polycyclic aromatic hydrocarbons. J Pharmacol Exp Ther 2003; 304:145-55.
4. Wei LH, Lai KP, Chen CA, Cheng CH, Huang YJ, Chou CH, Kuo ML, Hsieh CY. Arsenic trioxide prevents radiation-enhanced tumor invasiveness and inhibits matrix metalloproteinase-9 through downregulation of nuclear factor kappaB. Oncogene 2005; 24:390-8.
5. Zheng J, Deng YP, Lin C, Fu M, Xiao PG, Wu M. Arsenic trioxide induces apoptosis of HPV16 DNA-immortalized human cervical epithelial cells and selectively inhibits viral gene expression. Int J Cancer 1999; 82:286-92.
6. Tong T, Ji J, Jin S, Li X, Fan W, Song Y, Wang M, Liu Z, Wu M, Zhan Q. Gadd45a expression induces Bim dissociation from the cytoskeleton and translocation to mitochondria. Molecular and cellular biology 2005; 25:4488-500.
7. Makin GW, Corfe BM, Griffiths GJ, Thistlethwaite A, Hickman JA, Dive C. Damage-induced Bax N-terminal change, translocation to mitochondria and formation of Bax dimers/complexes occur regardless of cell fate. Embo J 2001; 20:6306-15.
8. Alley MC, Scudiero DA, Monks A, Hursey ML, Czerwinski MJ, Fine DL, Abbott BJ, Mayo JG, Shoemaker RH, Boyd MR. Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. Cancer Res 1988; 48:589-601.
9. Antonsson B, Montessuit S, Sanchez B, Martinou JC. Bax is present as a high molecular weight oligomer/complex in the mitochondrial membrane of apoptotic cells. J Biol Chem 2001; 276:11615-23.
10.Banerjee J, Ghosh S. Bax increases the pore size of rat brain mitochondrial voltage-dependent anion channel in the presence of tBid. Biochem Biophys Res Commun 2004; 323:310-4.
11.Scheffner M, Werness BA, Huibregtse JM, Levine AJ, Howley PM. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 1990; 63:1129-36.
12.Giafis N, Katsoulidis E, Sassano A, Tallman MS, Higgins LS, Nebreda AR, Davis RJ, Platanias LC. Role of the p38 mitogen-activated protein kinase pathway in the generation of arsenic trioxide-dependent cellular responses. Cancer Res 2006; 66:6763-71.
13.Kastan MB, Zhan Q, el-Deiry WS, Carrier F, Jacks T, Walsh WV, Plunkett BS, Vogelstein B, Fornace AJ, Jr. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell 1992; 71:587-97.
14.Takekawa M, Saito H. A family of stress-inducible GADD45-like proteins mediate activation of the stress-responsive MTK1/MEKK4 MAPKKK. Cell 1998;95:521-30.
15.Sugiyama T, Shimizu S, Matsuoka Y, Yoneda Y, Tsujimoto Y. Activation of mitochondrial voltage-dependent anion channel by apro-apoptotic BH3-only protein Bim. Oncogene 2002; 21:4944-56.
16.Hockenbery DM, Oltvai ZN, Yin XM, Milliman CL, Korsmeyer SJ. Bcl-2 functions in an antioxidant pathway to prevent apoptosis. Cell 1993; 75:241-51.
17.Voehringer DW, Meyn RE. Redox aspects of Bcl-2 function. Antioxid Redox Signal 2000; 2:537-50.
18. Ling YH, Jiang JD, Holland JF, Perez-Soler R. Arsenic trioxide produces polymerization of microtubules and mitotic arrest before apoptosis in human tumor cell lines. Mol Pharmacol 2002; 62:529-38.
19.Grad JM, Cepero E, Boise LH. Mitochondria as targets for established and novel anti-cancer agents. Drug Resist Updat 2001; 4:85-91.
20. Huibregtse JM, Scheffner M, Howley PM. Localization of the E6-AP regions that direct human papillomavirus E6 binding, association with p53, and ubiquitination of associated proteins. Molecular and cellular biology 1993; 13:4918-27.
21.Hildesheim J, Bulavin DV, Anver MR, Alvord WG, Hollander MC, Vardanian L, Fornace AJ, Jr. Gadd45a protects against UV irradiation-induced skin tumors, and promotes apoptosis and stress signaling via MAPK and p53. Cancer Res 2002;62:7305-15.
1. Cervical cancer. NIH Consens Statement 1996; 14:1-38; quiz 4p.
2. Lazo PA. The molecular genetics of cervical carcinoma. Br J Cancer 1999; 80:2008-18.
3. zur Hausen H. Intracellular surveillance of persisting viral infections. Human genital cancer results from deficient cellular control of papillomavirus gene expression. Lancet 1986; 2:489-91.
4. zur Hausen H. Papillomaviruses in anogenital cancer as a model to understand the role of viruses in human cancers. Cancer Res 1989; 49:4677-81.
5. Uslu R, Sanli UA, Sezgin C, Karabulut B, Terzioglu E, Omay SB, Goker E. Arsenic trioxide-mediated cytotoxicity and apoptosis in prostate and ovarian carcinoma cell lines. Clin Cancer Res 2000; 6:4957-64.
6. Shen ZY, Shen J, Cai WJ, Hong C, Zheng MH. The alteration of mitochondria is an early event of arsenic trioxide induced apoptosis in esophageal carcinoma cells. Int J Mol Med 2000; 5:155-8.
7. Maeda H, Hori S, Nishitoh H, Ichijo H, Ogawa O, Kakehi Y, Kakizuka A. Tumor growth inhibition by arsenic trioxide (As2O3) in the orthotopic metastasis model of androgen-independent prostate cancer. Cancer Res 2001; 61:5432-40.
8. Zheng J, Deng YP, Lin C, Fu M, Xiao PG, Wu M. Arsenic trioxide induces apoptosis of HPV16 DNA-immortalized human cervical epithelial cells and selectively inhibits viral gene expression. Int J Cancer 1999; 82:286-92.
9. Jing Yu HQ, Yunfeng Li, Yang Wang, Xueyan Zhang, Xiao Liang, Ming Fu and Chen Lin. Therapeutic Effect of Arsenic Trioxide (As2O3) on Cervical Cancer in Vitro and in Vivo through Apoptosis Induction cancer biology and therapy 2007; 6.
10.Vleminckx K, Vakaet L, Jr., Mareel M, Fiers W, van Roy F. Genetic manipulation of E-cadherin expression by epithelial tumor cells reveals an invasion suppressor role. Cell 1991; 66:107-19.
11. Williams TM, Lisanti MR The caveolin proteins. Genome biology 2004; 5:214.
12.Capozza F, Williams TM, Schubert W, McClain S, Bouzahzah B, Sotgia F, Lisanti MR Absence of caveolin-1 sensitizes mouse skin to carcinogen-induced epidermal hyperplasia and tumor formation. The American journal of pathology 2003; 162:2029-39.
13. Park DS, Lee H, Frank PG, Razani B, Nguyen AV, Parlow AF, Russell RG, Hulit J, Pestell RG, Lisanti MR Caveolin-1-deficient mice show accelerated mammary gland development during pregnancy, premature lactation, and hyperactivation of the Jak-2/STAT5a signaling cascade. Molecular biology of the cell 2002; 13:3416-30.
14.Wei LH, Lai KP, Chen CA, Cheng CH, Huang YJ, Chou CH, Kuo ML, Hsieh CY. Arsenic trioxide prevents radiation-enhanced tumor invasiveness and inhibits matrix metalloproteinase-9 through downregulation of nuclear factor kappaB. Oncogene 2005; 24:390-8.
15. Li HP, Chang YS. Epstein-Barr virus latent membrane protein 1: structure and functions. Journal of biomedical science 2003; 10:490-504.
16.Rimm DL, Koslov ER, Kebriaei P, Cianci CD, Morrow JS. Alpha 1(E)-catenin is an actin-binding and -bundling protein mediating the attachment of F-actin to the membrane adhesion complex. Proceedings of the National Academy of Sciences of the United States of America 1995; 92:8813-7.
17.Vasioukhin V, Fuchs E. Actin dynamics and cell-cell adhesion in epithelia. Current opinion in cell biology 2001; 13:76-84.
18.Morin PJ. beta-catenin signaling and cancer. Bioessays 1999; 21:1021-30.
19.Peifer M, Polakis P. Wnt signaling in oncogenesis and embryogenesis-a look outside the nucleus. Science 2000; 287:1606-9.
20.Bagnoli M, Tomassetti A, Figini M, Flati S, Dolo V, Canevari S, Miotti S. Downmodulation of caveolin-1 expression in human ovarian carcinoma is directly related to alpha-folate receptor overexpression. Oncogene 2000; 19:4754-63.
21. Bender FC, Reymond MA, Bron C, Quest AR Caveolin-1 levels are down-regulated in human colon tumors, and ectopic expression of caveolin-1 in colon carcinoma cell lines reduces cell tumorigenicity. Cancer research 2000; 60:5870-8.
22.Wiechen K, Sers C, Agoulnik A, Arlt K, Dietel M, Schlag PM, Schneider U. Down-regulation of caveolin-1, a candidate tumor suppressor gene, in sarcomas. The American journal of pathology 2001; 158:833-9.
23. Racine C, Belanger M, Hirabayashi H, Boucher M, Chakir J, Couet J. Reduction of caveolin 1 gene expression in lung carcinoma cell lines. Biochemical and biophysical research communications 1999; 255:580-6.
24. Barnes PJ, Karin M. Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. The New England journal of medicine 1997; 336:1066-71.
25. Baldwin AS, Jr. The NF-kappa B and I kappa B proteins: new discoveries and insights. Annual review of immunology 1996; 14:649-83.
26. Rossi A, Kapahi P, Natoli G, Takahashi T, Chen Y, Karin M, Santoro MG. Anti-inflammatory cyclopentenone prostaglandins are direct inhibitors of IkappaB kinase. Nature 2000; 403:103-8.
27. Karin M, Ben-Neriah Y. Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity. Annual review of immunology 2000; 18:621-63.
28. Kapahi P, Takahashi T, Natoli G, Adams SR, Chen Y, Tsien RY, Karin M. Inhibition of NF-kappa B activation by arsenite through reaction with a critical cysteine in the activation loop of Ikappa B kinase. The Journal of biological chemistry 2000; 275:36062-6.
29.Kuphal S, Poser I, Jobin C, Hellerbrand C, Bosserhoff AK. Loss of E-cadherin leads to upregulation of NFkappaB activity in malignant melanoma. Oncogene 2004; 23:8509-19.
30. Lo AK, Huang DP, Lo KW, Chui YL, Li HM, Pang JC, Tsao SW. Phenotypic alterations induced by the Hong Kong-prevalent Epstein-Barr virus-encoded LMP1 variant (2117-LMP1)in nasopharyngeal epithelial cells. International journal of cancer 2004; 109:919-25.
1. Einstein MH, Goldberg GL. Human papillomavirus and cervical neoplasia. Cancer Invest, 2002, 20 (7-8): 1080-1085
2. Dell G, Gaston K. Human papillomaviruses and their role in cervical cancer. Cell Mol Life Sci, 2001, 58 12-13): 1923-1942
3. Sherr CJ. Cancer cell cycles. Science, 1996, 274 (5293): 1672-1677
4. Khleif SN, DeGregori J, Yee CL, et al. Inhibition of cyclinD-CDK4/ CDK6 activity is associated with an E2F-mediated induction of cyclin kinase inhibitor activity. Proc Natl Acad Sci USA, 1996, 93 (9): 4350-4354
5. Murphy N, Ring M, Killalea AG, et al. p16~(INK4A) as a marker for cervical dyskaryosis: CIN and cGIN in cervical biopsies and ThinPrepsmears. J Clin Pathol, 2003,56 (1 ) :56-63
6. Kanao H, Enomoto T, Ueda Y, et al. Correlation between p14/p16~(INK4A) expression and HPV infection in uterine cervical cancer. Cancer Lett, 2004, 213(1): 31-37
7. Kalof AN, Evans MF, Simmons-Arnold L, et al. p16~(INK4A) immunoexpression and HPV in situ hybridization signal patterns: potential markers of high-grade cervical intraepithelial neoplasia. Am J Surg Pathol, 2005, 29 (5):674-679
8. Schorge JO, Lea KS, Elias KJ, et al. p16 as a molecular biomarker of cervical adenocarcinoma. Am J Obstet Gynecol, 2004, 190 (3):668-673
9. Lovec H, Sewing A, Lucibello FC, et al. Oncogenic activity of CyclinD1 revealed through cooperation with Ha2ras link between cell cycle control and malignant transformation. Oncogene, 1994, 9 (1): 3232326
10. Xiong Y, Connolly T, Fucher B, et al. Human D type cyclin. Cell, 1991,65:6911
11. Kato J.Matsushime H.Hiebert sw, et al. Direct binding of CyclinD to the retinoblastoma gene product (pRb) and pRb phosphorylation by the Cyclin D - dependent kinase cdk4. Genes Dev , 1993 ,7 :3311
12. Sheer CJ. G1 phase progression: cycling on cue. Cell, 1994 ,79 : 5511
13. Hosokawa Y.Arnold A. CyclinD1/ PRAD1 as a central target in oncogenesis. J Lab Clin Med, 1996,127 (3) 2461
14. Hall P A, Levison D A, Woods A L, et al. Proliferating cell nuclear antigen ( PCNA) immunolocalization in paraffin section :an index of cell proliferation with evidence of deregulated expression in somme neoplasms. J Pathol, 1990,162:285-294.
15. Woods A L, Hall P A .Shepherd N A, et al. The assessment of Proliferating cell nuclear antigen ( PCNA) immunostaining inprimary gast rointestinal lymphomas and it s relationship to histologycal grade ,S + G2 + M phase fraction (flow cytometric analysis) and prognosis. Histopathology, 1991, 19:21 -27.
16. Hiroyuki Miki MD, Hirotaka Yamada, Keiji Mitamura. Involvement p38 MAPK in apoptotic and proliferative alteration in human colorectal cancers. Anticancer Research, 1999,19 :5283 - 5292.
17. Lee C S. Differences in cell proliferation and prognostic significance of proliferation cell nuclear antigen and ki-67 antigen immunoreactivity in insitu and invasive carcinomas of the extrahepatic biliary tract. Cancer, 1996 , 78:1881-1887.
18. Thomas H, Nasim M M, Sarraf C E, et al. Proliferating cell nuclear antigen ( PCNA ) immunostiaining a prognostic factor in ovarian cancer ? Br J Cancer, 1995,71 :357 - 362.
19. Oya M, Yao T, Nagai E, et al. Metastasizing int ramucosal gastric carcinomas , well differentiatieal type and proliferative activity using proliferative cell nuclear antigen and ki267. Cancer, 1995 , 75 :926 - 935.
20. D Errico A, Garbisa S , Liotta L A, et al. Augmentation of type IV Collagenase , Lamini receptor, and ki267 proliferation antigen associated with human colon , gastric, and breast carcinoma progression. Mod Patho, 1991, 4 :239 - 246.
21. Hess J, Angel P, Schorpp- Kistner M. AP- 1 subunits: quarrel and harmony among siblings. J Cell Sci, 2004, 117(Pt 25):5 965
22. Fujioka S, Niu J, Schmidt C, et al. NF- κb and AP-1 connection: mechanism of NF- κB dependent regulation of AP-1 activity. Mol Cell Biol, 2004,24(17):7 806
23. Jiang X H , Wong B C , Lin M C ,et al. Functional p53 is required for triptolide induced apoptosis and AP-1 and nuclear factor-kappaB activation in gastric cancer cells. Oncogene, 2001, 20 (55):8009 - 8018.
24. Stein B, Baldwin A S, Ballard D W, et al. Cross-coupling of the NF-kappa B p65 and Fos /Jun transcription factors produces potentiated biological function. EMBO J, 1993, 12 (10) :3879- 3991.
25. Li J J, Westergaard C, Ghosh P, et al. Inhibitors of both nuclear factor-kappaB and activator protein-1 activation block the neoplastic transformation response. Cancer Res, 1997, 57( 16): 3569- 3576.
© 2004-2018 中国地质图书馆版权所有 京ICP备05064691号 京公网安备11010802017129号 地址：北京市海淀区学院路29号 邮编：100083 电话：办公室：(+86 10)66554848；文献借阅、咨询服务、科技查新：66554700 |